AGRX News and Press, Agile Therapeutics Inc. From 03/09/21

Evofem recently launched the first new non-hormonal birth control option in decades. Clinical efficacy falls short of the copper IUD, PARAGARD, but that device I believe may come with significant side effects. A trend in birth control centered on the woman's quality of life (safet...

PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will present at two investor conferences in March. H.C. Wainwright Global Life Scie...

Image source: The Motley Fool. Agile Therapeutics (NASDAQ: AGRX) Q4 2020 Earnings Call Mar 01, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Agile Therapeutics (AGRX) Q4 2020 Earnings Call Transcript

Agile Therapeutics, Inc. (AGRX) Q4 2020 Earnings Conference Call March 1, 2021 16:30 ET Company Participants Matthew Riley - Investor Relations Alfred Altomari - Chairman, President & Chief Executive Officer Dennis Reilly - Senior Vice President & Chief Financial Officer Conference Ca...

Agile Therapeutics (AGRX): Q4 GAAP EPS of -$0.20 beats by $0.03.Revenue of $0.75M misses by $0.26M.Cash, cash equivalents and marketable securities of $54.5M.Shares +3.3%.Press Release For further details see: Agile Therapeutics EPS beats by $0.03, misses on revenue

Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available Achieved Gross Revenue Target In Fourth Quarter 2020, Reflecting Initial Stocking of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system Announces Agreem...

Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2020 financial results after the market close on Mon...

Agile Therapeutics' recently approved Twirla patch is starting to hit the market. The company's market cap is significantly lower than it was a year ago. Agile Therapeutics management has recently given guidance around cash positioning for calendar year 2021. Twirla's commerci...

Agile Therapeutics (AGRX) reports estimated cash and equivalents of $54.5M as of Dec. 31, 2020, which it says will be sufficient to meet operating costs through the end of this year, presenting at the JPMorgan Healthcare Conference today.The company expects its Q4 gross revenue to be ~$1M,&#x...

Today, we look at a small cap concern in the contraceptive space called Agile Therapeutics. The company recently had approved a potentially best of breed device in this niche that is just beginning its marketing rollout. A full investment analysis is provided in the paragraphs bel...